The University of Chicago Header Logo

Connection

Scott E. Eggener to Neoplasm Staging

Back to Details
This is a "connection" page, showing publications Scott E. Eggener has written about Neoplasm Staging.
Scott E. Eggener
Connection Strength
2.786
Neoplasm Staging
  1. Active Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer. J Urol. 2022 02; 207(2):262-264.
    View in: PubMed
    Score: 0.141
  2. Prostate Cancer Outcomes Following Solid-Organ Transplantation: A SEER-Medicare Analysis. J Natl Cancer Inst. 2020 08 01; 112(8):847-854.
    View in: PubMed
    Score: 0.129
  3. National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy. Urol Oncol. 2020 08; 38(8):687.e13-687.e18.
    View in: PubMed
    Score: 0.127
  4. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. J Clin Oncol. 2020 05 01; 38(13):1474-1494.
    View in: PubMed
    Score: 0.124
  5. SPARED Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer. J Urol. 2019 11; 202(5):952-958.
    View in: PubMed
    Score: 0.122
  6. Indications, evolving technique, and early outcomes with robotic retroperitoneal lymph node dissection. Curr Opin Urol. 2018 09; 28(5):461-468.
    View in: PubMed
    Score: 0.113
  7. Late Relapse of Nonseminomatous Germ Cell Tumor 24 Years Later. Urology. 2018 Dec; 122:16-18.
    View in: PubMed
    Score: 0.113
  8. Impact of Perioperative Infection on Cancer Specific Survival after Nephrectomy for Renal Cell Carcinoma. J Urol. 2017 11; 198(5):1027-1032.
    View in: PubMed
    Score: 0.104
  9. AUA Policy Statement on the Use of Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer. J Urol. 2017 10; 198(4):832-838.
    View in: PubMed
    Score: 0.103
  10. Extraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 Prostate Cancer. Eur Urol. 2017 09; 72(3):455-460.
    View in: PubMed
    Score: 0.101
  11. Risk of lymph node metastases in pathological gleason score=6 prostate adenocarcinoma: Analysis of institutional and population-based databases. Urol Oncol. 2017 01; 35(1):31.e1-31.e6.
    View in: PubMed
    Score: 0.099
  12. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer. Eur Urol. 2017 03; 71(3):476-482.
    View in: PubMed
    Score: 0.097
  13. Management of Low-Stage Testicular Seminoma. Urol Clin North Am. 2015 Aug; 42(3):287-98.
    View in: PubMed
    Score: 0.091
  14. Population-based analysis of treatment modalities and survival for clinically localized small-cell carcinoma of the prostate. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):286-91.
    View in: PubMed
    Score: 0.085
  15. A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol. 2013 Jan; 189(1 Suppl):S19-25; discussion S25.
    View in: PubMed
    Score: 0.077
  16. TNM staging for renal cell carcinoma: time for a new method. Eur Urol. 2010 Oct; 58(4):517-9; discussion 519-21.
    View in: PubMed
    Score: 0.065
  17. Focal therapy for prostate cancer: possibilities and limitations. Eur Urol. 2010 Jul; 58(1):57-64.
    View in: PubMed
    Score: 0.063
  18. Re: Effectiveness of antibiotics given to asymptomatic men for an increased prostate specific antigen. S. Baltaci, E. Suer, A. H. Haliloglu, M. I. Gokce, A. H. Elhan and Y. Beduk. J Urol 2009; 181: 128-132. J Urol. 2009 Jul; 182(1):396-7.
    View in: PubMed
    Score: 0.060
  19. Length of positive surgical margin after radical prostatectomy as a predictor of biochemical recurrence. J Urol. 2009 Jul; 182(1):139-44.
    View in: PubMed
    Score: 0.059
  20. Editorial comment on: Analysis of T1c prostate cancers treated at very low prostate-specific antigen levels. Eur Urol. 2009 Mar; 55(3):616.
    View in: PubMed
    Score: 0.056
  21. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol. 2007 Dec; 178(6):2260-7.
    View in: PubMed
    Score: 0.053
  22. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. J Urol. 2007 Mar; 177(3):937-42; discussion 942-3.
    View in: PubMed
    Score: 0.051
  23. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. J Urol. 2006 Oct; 176(4 Pt 1):1399-403.
    View in: PubMed
    Score: 0.050
  24. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol. 2006 Jul 01; 24(19):3101-6.
    View in: PubMed
    Score: 0.049
  25. Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy. J Urol. 2005 Apr; 173(4):1150-5.
    View in: PubMed
    Score: 0.045
  26. Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy. J Clin Oncol. 2023 06 01; 41(16):3009-3018.
    View in: PubMed
    Score: 0.039
  27. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. J Urol. 2021 Mar; 205(3):769-779.
    View in: PubMed
    Score: 0.033
  28. Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer. J Urol. 2020 Apr; 203(4):706-712.
    View in: PubMed
    Score: 0.031
  29. Impact of preoperative prostate magnetic resonance imaging on the surgical management of high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2020 03; 23(1):172-178.
    View in: PubMed
    Score: 0.030
  30. Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline. J Urol. 2019 08; 202(2):272-281.
    View in: PubMed
    Score: 0.030
  31. Nationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle. Eur Urol Oncol. 2020 04; 3(2):198-206.
    View in: PubMed
    Score: 0.030
  32. International and Multi-institutional Assessment of Factors Associated With Performance and Quality of Lymph Node Dissection During Radical Nephrectomy. Urology. 2019 Jul; 129:132-138.
    View in: PubMed
    Score: 0.030
  33. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? Future Oncol. 2019 May; 15(15):1683-1695.
    View in: PubMed
    Score: 0.030
  34. Predominantly cystic clear cell renal cell carcinoma and multilocular cystic renal neoplasm of low malignant potential form a low-grade spectrum. Virchows Arch. 2018 Jul; 473(1):85-93.
    View in: PubMed
    Score: 0.028
  35. African-American Prostate Cancer Disparities. Curr Urol Rep. 2017 Aug 14; 18(10):81.
    View in: PubMed
    Score: 0.026
  36. Low-risk Prostate Cancer: Identification, Management, and Outcomes. Eur Urol. 2017 08; 72(2):238-249.
    View in: PubMed
    Score: 0.026
  37. The impact of days off between cases on perioperative outcomes for robotic-assisted laparoscopic prostatectomy. World J Urol. 2016 Feb; 34(2):269-74.
    View in: PubMed
    Score: 0.023
  38. Differential use of partial nephrectomy for intermediate and high complexity tumors may explain variability in reported utilization rates. J Urol. 2013 Jun; 189(6):2047-53.
    View in: PubMed
    Score: 0.019
  39. Short (= 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy. BJU Int. 2013 Apr; 111(4):559-63.
    View in: PubMed
    Score: 0.018
  40. Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2013 Feb 01; 85(2):378-84.
    View in: PubMed
    Score: 0.018
  41. Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel. BJU Int. 2012 Oct; 110(7):942-8.
    View in: PubMed
    Score: 0.018
  42. Local staging of prostate cancer with MRI. Diagn Interv Radiol. 2012 Jul-Aug; 18(4):365-73.
    View in: PubMed
    Score: 0.018
  43. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int. 2011 Sep; 108(5):701-5.
    View in: PubMed
    Score: 0.017
  44. Gleason 6 prostate cancer in one or two biopsy cores can harbor more aggressive disease. J Endourol. 2011 Apr; 25(4):699-703.
    View in: PubMed
    Score: 0.017
  45. Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol. 2010 Jul; 184(1):69-73.
    View in: PubMed
    Score: 0.016
  46. The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer. Urology. 2010 Jun; 75(6):1431-5.
    View in: PubMed
    Score: 0.016
  47. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes? J Urol. 2008 Dec; 180(6):2436-40.
    View in: PubMed
    Score: 0.014
  48. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol. 2008 Nov; 180(5):1964-7; discussion 1967-8.
    View in: PubMed
    Score: 0.014
  49. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol. 2008 May; 53(5):950-9.
    View in: PubMed
    Score: 0.013
  50. Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res. 2007 Jul 15; 13(14):4130-8.
    View in: PubMed
    Score: 0.013
  51. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol. 2007 Aug; 178(2):493-9; discussion 499.
    View in: PubMed
    Score: 0.013
  52. Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease. Urology. 2005 Jul; 66(1):156-60.
    View in: PubMed
    Score: 0.011
  53. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J Urol. 2003 Apr; 169(4):1219-28.
    View in: PubMed
    Score: 0.010
  54. p53 and microvessel density in primary resection specimens of superficial bladder cancer. J Urol. 2002 Mar; 167(3):1469-74.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.